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OBJECTIVES We examined the prognostic implications of the absolute level and rate of increase of creatine
kinase (CK) elevation after primary percutaneous coronary intervention (PCI).
BACKGROUND Peak creatine kinase (CKpeak) and the rate of CK increase are related to reperfusion success
and clinical outcomes after thrombolytic therapy for acute myocardial infarction (AMI). The
utility of routine serial CK monitoring after primary PCI, in which normal antegrade blood
flow is restored in most patients, is unknown.
METHODS In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Compli-
cations (CADILLAC) trial, 1,529 patients with AMI randomized to either stenting or
balloon angioplasty, each with or without abciximab, had CK levels determined at baseline
and at 8  1 h, 16  1 h, and 24  1 h after PCI.
RESULTS The CKpeak occurred at baseline in 3.9% of patients, at 8  1 h in 69.6%, at 16  1 h in
20.0%, and at 24  1 h in 6.5%. The CK levels at all post-procedural time points were
significantly higher in patients who died compared with the one-year survivors, as was CKpeak
(mean, 2,865 U/l vs. 1,885 U/l, respectively, p 0.001). By multivariate analysis, CKpeak was
a significant predictor of one-year mortality (hazard ratio  2.15, p  0.0002), independent
from post-PCI Thrombolysis In Myocardial Infarction (TIMI) flow. Both the improvement
in left ventricular ejection fraction from baseline to seven months and its absolute level were
inversely correlated with CKpeak (p 0.001 for both). In contrast, the time to CKpeak was not
an independent predictor of mortality or myocardial recovery.
CONCLUSIONS The CKpeak after primary PCI is a powerful predictor of one-year mortality independent of
other clinical and angiographic measures. (J Am Coll Cardiol 2006;47:951–61) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.003the American College of Cardiology Foundation
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tn the pre-reperfusion era, the peak level of serum creatine
inase (CK) measured within the first 24 to 48 h after acute
yocardial infarction (AMI), as a reflection of infarct size,
as found to be strongly related to subsequent mortality (1).
owever, the prognostic significance of peak cardiac en-
yme level elevation after reperfusion therapy is less clear.
arly reperfusion therapy during evolving AMI is known to
ncrease the absolute peak CK level and the rapidity with
hich the apex of the peak is reached (2). Although a rapid
ncrease in CK is a marker of effective thrombolysis (3,4),
ome studies indicate that larger (5) and earlier (6) enzyme
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enter, New York, New York; ‡William Beaumont Hospital, Royal Oak, Michigan;
Mid Carolina Cardiology, Charlotte, North Carolina; St. Luke’s Hospital, Kansas
ity, Missouri; ¶St. Joseph’s Hospital, Syracuse, New York; #St. Joseph Regional
edical Center, Milwaukee, Wisconsin; **Sahlgrenska University Hospital, Göte-
org, Sweden; ††Allegheny General Hospital, Pittsburgh, Pennsylvania; and the
‡Duke Clinical Research Institute, Durham, North Carolina. Funding for the
ADILLAC trial was provided by Guidant Corporation.t
Manuscript received June 15, 2005; revised manuscript received July 25, 2005,
ccepted August 20, 2005.eaks are associated with increased rates of adverse out-
omes after pharmacologic reperfusion therapy. In recent
ears, primary percutaneous coronary intervention (PCI)
as emerged as the preferred reperfusion modality for AMI
7). Whether CK elevations have similar prognostic implica-
ions after primary PCI as thrombolytic therapy, given the
igher rates of Thrombolysis In Myocardial Infarction (TIMI)
ow grade 3 and reperfusion success with the catheter-based
trategy, is unknown and has not been studied.
We therefore performed a post hoc analysis of the
atabase from a large, prospective, multicenter, randomized
tudy of mechanical reperfusion therapies in AMI to deter-
ine the relationship between post-PCI CK levels, kinetics,
nd outcomes.
ETHODS
etails of the Controlled Abciximab and Device Investigation
o Lower Late Angioplasty Complications (CADILLAC)
rial have been previously reported (8). Briefly, 2,082 pa-
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CK Elevation and Prognosis After Primary PCI March 7, 2006:951–61ients 18 years of age with AMI and symptom onset
ithin 12 h undergoing primary PCI were randomized to
rimary balloon angioplasty versus stent implantation, each
ith or without abciximab. The principal clinical exclusion
riteria were cardiogenic shock and the prior use of throm-
olytic therapy for the present admission. Angiographic
nclusion criteria included a native coronary artery culprit
essel with a reference diameter of 2.5 to 4.0 mm and a
esion length 64 mm. Clinical follow-up continued for
ne year. Protocol-specified, angiographic 7-month
ollow-up was completed in 656 patients (73% of a 900-
atient pre-specified cohort). Quantitative coronary angiog-
aphy and ventriculographic assessment were performed
sing dedicated software (QCA-CMS, MEDIS, Leiden,
he Netherlands) at an independent core angiographic
aboratory at the Cardiovascular Research Foundation, New
ork, New York. Left ventricular ejection fraction (LVEF)
as calculated using the length-area method (9). Antegrade
oronary blood flow was evaluated using the TIMI scale
10). Myocardial blush (11) and changes in electrocardio-
raphic ST-segment elevation (12) were determined in two
ormal CADILLAC sub-studies consisting of 1,301 and
00 patients, respectively.
K measurements. Protocol-specified blood sampling for
K levels was performed at baseline and at 8  1 h, 16 
h, and 24  1 h after PCI. Measurement of serum total
K levels was performed according to local hospital stan-
ards. Outcomes were examined stratified by peak CK levels
CKpeak), divided into four equal quartiles.
nd points and statistical analysis. The primary study
nd point was a composite of major adverse cardiac events,
efined as death from any cause, reinfarction, repeat target
essel revascularization as a result of ischemia, or disabling
troke. The components of the composite end point have
een previously defined (8). Outcomes were evaluated as a
unction of absolute CKpeak level (as both a continuous and
categorical [quartile] measure), and by the timing of
Kpeak. Categorical data were compared using the Fisher
xact test. Continuous variables are presented as mean 
D and were compared using the Student t test or one-way
nalysis of variance as appropriate. For comparison of
ultiple groups with ordinal categorization, the trend in the
inomial proportions of categorical variables was analyzed
Abbreviations and Acronyms
AMI  acute myocardial infarction
CADILLAC  Controlled Abciximab and Device
Investigation to Lower Late Angioplasty
Complications
CK  creatine kinase
CKpeak  peak creatine kinase
LVEF  left ventricular ejection fraction
PCI  percutaneous coronary intervention
TIMI  Thrombolysis In Myocardial Infarctionsing the Cochran-Armitage test, and analysis of variance sas used to test for linear trends across the means of
ontinuous variables. Clinical outcomes were presented as
aplan-Meier survival estimates and were compared using
he log-rank test. Independent predictors of CKpeak were
etermined by multiple linear regression using stepwise
election (entry and exit criteria of p  0.10 and p  0.15,
espectively), considering CKpeak as a log-transformed con-
inuous variable. Independent predictors of survival were
etermined with Cox proportional hazard regression anal-
sis using stepwise selection of all of the parameters in Table
with entry and exit criteria of p  0.10 and p  0.15,
espectively. For all analyses, a two-tailed p  0.05 was
onsidered statistically significant.
ESULTS
aseline features. Of 2,082 patients, CK values were
vailable at baseline and at all three post-PCI pre-specified
ime points in 1,529 patients (73.4%), who are the study
ohort. Baseline characteristics and procedural results were
imilar in patients with compared to those without complete
K data (Table 2).
Clinical characteristics and procedural results of patients
tratified by CKpeak are shown in Table 1. Patients with
igher CKpeak values were more likely to be younger, male,
nd non-diabetic, and to have a shorter time from symptom
nset to PCI than those with lower CKpeak values. The
nfarct artery of patients with a greater CKpeak value was
arger in diameter and most commonly the left anterior
escending vessel, and baseline global and regional left
entricular function was depressed. Spontaneous reperfu-
ion before intervention was also less frequent in patients
ith a greater CKpeak value, and the post-procedure rates of
ormalized TIMI flow grade and myocardial blush were
ower than in patients with a greater CKpeak value.
attern and determinants of CK elevation. For the entire
tudy population, the mean CKpeak was 1,921  1,723 U/l.
y multivariate analysis, the independent correlates of
Kpeak were left anterior descending culprit artery (odds
atio [95% confidence interval]  1.90 [1.43 to 2.52], p 
.0001), pre-procedural TIMI flow grade 0 to 2 (5.26 [3.23
o 9.09], p 0.0001), younger age (1.02 [1.01 to 1.03], p 
.0001), and reduced baseline LVEF (1.05 [1.04 to 1.06],
 0.0001). Of the variables listed in Table 1, none of the
ost-procedural angiographic findings were independently
redictive of CKpeak.
The mean CK level at each time period for patients
ithin each CKpeak quartile are shown in the upper panel of
igure 1. The CKpeak occurred at the baseline measure in
.9% of patients, at 8  1 h in 69.6% of patients, at 16 
h in 20.0% of patients, and at 24 1 h in 6.5% of patients.
s seen in the lower panel of Figure 1, the greater the
Kpeak, the earlier the time the peak was achieved.
The CK levels at all time points as well as at CKpeak wereimilar in patients stratified by randomization arm (Fig. 2).
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March 7, 2006:951–61 CK Elevation and Prognosis After Primary PCIeither stent implantation nor abciximab use were inde-
endent predictors of CKpeak by multivariate analysis.
Kpeak and outcomes. The one-year all-cause mortality
as 3.8%. Although similar at baseline, CK levels at all
ost-procedural time points (Fig. 3, top panel) and CKpeak
2,865  2,158 U/l vs. 1,885  1,694 U/l, respectively, p 
.0001) were significantly higher in patients who died
ompared with those who survived to one-year follow-up.
imilarly, the mean CK level at each time point (Fig. 3,
ottom panel) and CKpeak (2,866  2,191 U/l vs. 1,846 
,664 U/l, respectively, p  0.001) in those who died versus
n one-year survivors were significant predictors of one-year
ortality when confined to patients in whom TIMI flow
rade 3 was restored after PCI.
Clinical and angiographic outcomes in patients stratified
y CKpeak as a categorical variable are shown in Table 3 and
n Figure 4. Mortality at 30 days and at 1 year increased
ignificantly with an increasing CKpeak level. There was a
ignificant inverse relationship between CKpeak and both the
bsolute LVEF at seven months and its improvement from
able 1. Baseline Characteristics in Patients Stratified by CKpeak
Quartile 1
CKpeak <669
(n  382)
Qua
669 < CK
(n 
linical features
Age, yrs 61.2  12.0 59.7
Male gender, % 66.5 7
Diabetes mellitus, % 21.5 1
Current smoker, % 41.5 4
Hypercholesterolemia, % 43.5 3
Hypertension, % 52.9 4
Previous myocardial infarction, % 15.5 1
Killip class 2 to 3, % 12.6
Angina within one month of
admission, %
35.8 2
Symptom onset to angioplasty, h 5.4  3.5 5.2
ngiographic features (baseline)
Three-vessel disease, % 18.3 1
Infarct vessel  left anterior
descending, %
32.7 2
Reference vessel diameter, mm 2.90  0.52 3.00
Minimal luminal diameter, mm 0.60  0.53 0.34
Diameter stenosis, % 79.1  18.0 88.4
TIMI flow grade 3, % 45.0 2
Left ventricular ejection fraction, % 59.6  11.7 57.2
rocedural results
Procedure duration, h 1.2  0.5 1.1
Stent implanted, % 54.7 5
Abciximab administered, % 53.1 5
Minimal luminal diameter, mm 2.25  0.47 2.26
Diameter stenosis, % 23.8  10.3 25.5
TIMI flow grade 3, % 98.1 9
Myocardial blush grade 3, % 23.3 2
Complete ST-segment elevation
resolution*, %
73.5 6
Kpeak, U/l 341  188 1,018
Complete recovery of ST-segment elevation was defined as 70% reduction in the
ithin 4 h after the procedure (12).
Abbreviations as in Table 2.aseline to follow-up (Table 3, Fig. 5). No relationship was oresent between CKpeak and the rates of reinfarction, stroke,
r target vessel revascularization (Table 3).
Because in 89.6% of the study population CKpeak
ccurred within 8 to 16 h after PCI, a secondary analysis
xamined 30-day and 1-year survival among the 1,871
atients (89.9% of the entire CADILLAC study popu-
ation) with at least one available CK measurement at
ither of those time points. When stratified by CKpeak
uartiles, mortality increased significantly with increasing
Kpeak (30-day mortality in quartiles 1 through 4: 0.4%,
.6%, 1.1%, 4.5%, respectively; p  0.0001; 1-year
ortality: 2.2%, 2.2%, 3.7%, 7.6%, respectively; p 
.0001).
Kpeak kinetics and outcomes. Baseline features and the
utcomes of patients stratified by the timing of CKpeak are
hown in Table 4. Among the 96.1% of patients in whom
K peaked after PCI, a more rapid time to CKpeak was
ssociated with younger age, infarction of the left anterior
escending artery, less frequent spontaneous reperfusion
efore PCI, abciximab use, a shorter time from symptom
2
1,458
)
Quartile 3
1,458 < CKpeak <2,667
(n  382)
Quartile 4
CKpeak >2,667
(n  383) p Trend
.9 59.3  12.1 57.8  12.3 0.0001
77.0 75.8 0.002
15.4 12.0 0.0002
45.0 49.3 0.005
36.9 36.3 0.04
47.6 41.0 0.002
13.1 10.2 0.02
9.7 12.7 0.93
26.6 24.7 0.001
4 5.0  3.3 4.8  3.3 0.008
17.6 15.9 0.77
33.0 55.9 0.0001
56 3.02  0.53 3.02  0.57 0.002
48 0.23  0.46 0.16  0.39 0.0001
.6 92.6  14.6 94.5  13.4 0.0001
12.2 6.9 0.0001
.1 54.7  10.9 49.3  11.9 0.0001
5 1.1  0.6 1.2  0.5 0.68
58.6 54.6 0.99
54.5 50.7 0.59
53 2.30  0.50 2.26  0.52 0.65
.7 24.4  11.0 24.9  13.3 0.41
96.6 92.6 0.0002
11.5 10.8 0.0001
62.6 52.9 0.0003
4 1,988  352 4,333  1,588 0.0001
d ST-segment elevation score between electrocardiograms recorded before PCI andrtile
peak <
382
 11
3.0
9.1
1.9
8.7
7.6
5.7
9.2
7.3
 3.
2.8
6.2
 0.
 0.
 16
3.9
 11
 0.
8.1
3.1
 0.
 12
6.6
2.9
8.0
 22
summenset to PCI, and a greater CKpeak value. A faster time to
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CK Elevation and Prognosis After Primary PCI March 7, 2006:951–61Kpeak was also associated with reduced LVEF at baseline
nd at follow-up, although the extent of improvement in
VEF from baseline to follow-up was independent of time to
Kpeak. There was also no significant relationship between the
apidity to CKpeak on mortality at 30 days or 1 year.
In comparison with patients in whom the CKpeak occurred
fter PCI, the 3.9% of patients in whom the CKpeak had
lready occurred at baseline had a longer time from symptom
nset to PCI, were less likely to have TIMI flow grade 3 at
aseline, and had smaller infarct vessels with less frequent stent
mplantation. Despite a lower mean CKpeak value, patients
ith CKpeak at baseline had greater mortality at 30 days and at
year compared with patients with CKpeak at 8 or 16 h.
ultivariate predictors of mortality. By Cox proportional
azard regression analysis, CKpeak as a continuous variable,
ut not the timing of CKpeak, was an independent predictor
f one-year mortality (Table 5). When CKpeak was entered
nto the multivariate model as a categorical variable, the
azard ratios and 95% confidence intervals for one-year
ortality with quartile 1 (CKpeak 669 U/l) as reference
HR  1.00) were: for quartile 2 (669  CKpeak 1,458
/l), HR  1.77 [0.42 to 7.42], p  0.44; for quartile 3
1,458  CKpeak 2,667 U/l), HR  2.97 [0.81 to 10.86],
 0.10; and for quartile 4 (CKpeak 2,667 U/l), HR 
.63 [1.61 to 19.62], p  0.007.
In a secondary analysis, CKpeak as a continuous variable
emained an independent correlate of one-year survival
hen the multivariate model was applied to the 1,871
atients with an available CK measurement at 8 to 16 h
Table 2. Baseline Characteristics and In-Hosp
Those Excluded for Missing CK Data
Clinical features
Age, yrs
Male gender, %
Diabetes mellitus, %
Previous myocardial infarction, %
Killip class 2 to 3, %
Time from symptom onset to angioplasty, h
Angiographic features
Three-vessel disease, %
Infarct vessel  left anterior descending, %
TIMI flow grade 3, before, %
Baseline left ventricular ejection fraction, %
Procedural results
Stent implanted, %
Abciximab administered, %
TIMI flow grade 3, after, %
Minimal luminal diameter, mm
Diameter stenosis, %
TIMI flow grade 3, after, %
Myocardial blush grade 3, %
CKpeak  peak creatine kinase level; PCI  percutaneou
Infarction.fter PCI (HR  2.52 [1.58 to 4.03], p  0.0001). iISCUSSION
he principal findings of the present study are: 1) despite
chievement of TIMI flow grade 3 in 90% of patients,
Kpeak after primary PCI is a powerful independent deter-
inate of one-year mortality; and 2) the CKpeak after
rimary PCI is also inversely related to recovery of left
entricular function.
revious studies. Before the advent of reperfusion therapy
or AMI, the peak level of myocardial enzymes was shown
o correlate with infarct size and survival (1,13,14). More
ecently, the Global Utilization of Streptokinase and TPA
or Occluded Coronary Arteries (GUSTO)-IIb investiga-
ors reported that the extent of CK elevation is an indepen-
ent predictor of mortality in a wide spectrum of patients
ith acute coronary syndromes, including those treated with
eperfusion therapy (15). However, experimental studies
ave suggested that enzymatic measures after early reperfu-
ion overestimate infarct size (16,17). Furthermore, in
ecent reports higher enzyme peaks after thrombolysis
redicted a lower LVEF and an increased risk of congestive
eart failure and death (5,18). Prior studies have also
eached conflicting conclusions regarding the prognostic
mplications of the time to CKpeak after thrombolysis. An
arly CKpeak after thrombolysis has been associated with
uccessful reperfusion in some studies (3,4), but with a
arger infarct size in others (6). In the present study as well,
higher CKpeak was associated with increased 30-day and
-year mortality. Unlike thrombolytic studies in which flow
n the infarct artery before reperfusion therapy is not known,
utcomes in Study Patients Compared With
Study
pulation
 1,529)
Patients Excluded
for Missing CK Data
(n  553) p
5  12.1 60.2  12.2 0.24
73.0 73.1 0.99
17.0 15.6 0.46
13.6 13.9 0.88
11.1 10.4 0.75
0  3.2 5.6  3.7 0.14
16.2 13.9 0.24
37.0 36.2 0.75
22.0 22.3 0.90
2  12.0 54.7  12.3 0.45
56.5 57.5 0.69
52.8 53.9 0.69
96.0 94.5 0.14
7  0.50 2.25  0.52 0.43
6  11.9 24.5  13.5 0.84
96.0 94.5 0.14
17.1 18.5 0.61
nary intervention; TIMI  Thrombolysis In Myocardialital O
Po
(n
59.
5.
55.
2.2
24.n the present study we were able to ascertain that a higher
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March 7, 2006:951–61 CK Elevation and Prognosis After Primary PCIKpeak was associated with reduced rates of spontaneous
eperfusion before angioplasty. Given the beneficial prog-
ostic implications of normalized flow in the infarct artery
t presentation, it is plausible that this factor is an important
igure 1. Mean creatine kinase (CK) levels and the timing of peak levels in
oronary intervention (PCI). p trend  0.0001 for all comparisons within
t time point. p trend  0.0001 for all within-group comparisons.igure 2. Creatine kinase (CK) levels in patients stratified by randomization a
ransluminal coronary angioplasty.eterminant of myocardial salvage in the setting of primary
ngioplasty.
TIMI flow grade 3 is present in 60% of patients after
hrombolysis; this observation may explain some of the
ts stratified by CKpeak. (Top) CK levels at baseline and after percutaneous
idual time points. (Bottom) proportion of patients with CKpeak occurringpatienrm. PCI  percutaneous coronary intervention; PTCA  percutaneous
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CK Elevation and Prognosis After Primary PCI March 7, 2006:951–61eterogeneity of findings in the aforementioned studies. In
his regard it is noteworthy that no large-scale study has
xamined the implications of the absolute level and rate of
ncrease of CK after primary PCI, in which TIMI flow
rade 3 may be restored in 90% of patients. Biomarkers
ther than CK, however, have been examined in the setting
f primary PCI. The cumulative extent of lactate dehydro-
enase release after primary PCI was found to be an
ndependent predictor of one-year mortality in a single
tudy (19). However, this enzyme, which does not peak
ntil 72 h, is not a convenient bedside tool and is
rognostically ineffective in patients who die within the first
ew days after AMI, the highest-risk period for mortality
20). For these reasons, the use of lactate dehydrogenase for
igure 3. Creatine kinase (CK) levels at baseline and after percutaneous
oronary intervention (PCI) in patients who survived (open bars) com-
ared with those who had died (solid bars) by one-year follow-up. Data are
resented as mean  SD. (Top) All patients (n  1,529). (Bottom)
atients with TIMI flow grade 3 after percutaneous coronary intervention
n  1,448).he diagnosis of AMI is no longer endorsed (21). In Contrast, serial measures of CK release are universally
btained as standard of care after AMI, and peak typically
ithin 24 h. As such, characterizing the prognostic impli-
ations of CK release after primary PCI is of potential
linical utility.
K elevation and outcomes after primary PCI. The
resent analysis shows that peak CK level is a powerful
redictor of one-year mortality after primary PCI, indepen-
ent of post-procedure TIMI flow grade. Although the
echanistic link between CK levels and survival is uncer-
ain, the significant inverse association between CKpeak and
he absolute improvement in LVEF from baseline to seven-
onth follow-up suggests that the increase in CK after
rimary PCI is a reflection of infarct size.
Unlike CKpeak, and in contrast to prior thrombolytic
rials (3,4), an earlier CK increase in the CADILLAC trial
as not associated with angiographic markers of enhanced
eperfusion such as higher rates of TIMI flow grade 3 and
ormal myocardial blush. Conversely, an early post-PCI
Kpeak was associated with higher maximum CK levels and
lower LVEF at baseline and at follow-up, in accordance
ith the findings of others (6). Whether the association
etween a rapidly increasing CK and reduced left ventricular
unction results from more rapid enzyme release by larger
nfarcts or whether it is an expression of reperfusion injury
22,23) is unknown. An association was also observed
etween CKpeak kinetics and survival, with a trend toward
igher mortality present in patients with later time to peak
nzyme increase, despite lower CKpeak. However, by mul-
ivariate analysis only CKpeak, and not time to peak, was an
ndependent predictor of survival. Finally, the small cohort
3.9%) of patients in whom the CKpeak was reached at
aseline (before PCI) had a different clinical and angio-
raphic profile than the rest, with longer times to reperfu-
ion and smaller infarct arteries. It is likely that the true
Kpeak may have occurred even earlier, possibly explaining
he trend toward higher mortality in this group despite
igher rates of pre-procedural spontaneous reperfusion (24).
orrelates of peak CK elevation. The strongest correlates
f CKpeak were left anterior descending culprit artery,
re-procedural TIMI flow grade 0 to 2, younger age, and
educed baseline LVEF. The greater CKpeak in left anterior
escending artery occlusion may be explained not only by
he larger myocardial territory supplied, but also by de-
reased reperfusion success in this territory (12). The fact
hat lack of spontaneous reperfusion in the infarct vessel
efore PCI was a multivariate predictor of CKpeak adds
urther credence to the concept of pharmacologic facilita-
ion of primary PCI to restore reperfusion as early as
ossible before definitive mechanical revascularization (25),
strategy currently undergoing clinical investigation. The
orrelation between reduced baseline LVEF and CKpeak
ikely reflects a greater amount of myocardium at risk and
ighlights the prognostic utility of assessing left ventric-
lar function during the index procedure. The lower
Kpeak in elderly patients and in those with prior MI
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March 7, 2006:951–61 CK Elevation and Prognosis After Primary PCIight be explained by reduction of myocardial mass and,
n diabetic patients, by lower myocardial expression of
K (26,27). Of note, abciximab use and stenting were
ot correlates of CKpeak in the CADILLAC trial, con-
istent with previous smaller studies (28,29). This obser-
ation is also consistent with the prior reported absence
f a relationship between these modalities and recovery of
eft ventricular function (30).
tudy limitations. Approximately 26% of patients were
xcluded from the present study because of missing CK
alues at one or more time points. Nevertheless, these
able 3. Clinical and Angiographic Outcomes of Patients Stratifi
Quartile 1
CKpeak < 669 669 <
0-day clinical follow-up
Death, % 0.5
Reinfarction, % 0.5
Disabling stroke, % 0.0
Ischemic target vessel revascularization, % 3.4
Composite major adverse cardiac events, % 4.2
-month angiographic follow-up*
LVEF, % 66.8  10.2 6
Change in LVEF from baseline to
follow-up, %
5.0  11.9
Minimal luminal diameter, mm 1.75  0.67 1
Diameter stenosis, % 38.6  20.7 3
Binary restenosis, % 27.9
Reocclusion of infarct artery, % 7.0
-yr clinical follow-up
Death, % 2.4
Reinfarction, % 2.4
Disabling stroke, % 0.3
Ischemic target vessel revascularization, % 16.2
Composite major adverse cardiac events, % 17.7
Follow-up coronary angiography, follow-up left ventriculography, and paired left ve
espectively. †p  0.0001 for quartile 4 compared with quartiles 1 through 3 combi
LVEF  left ventricular ejection fraction; other abbreviations as in Table 1.Figure 4. All-cause mortality among patients stratatients did not differ from those included with respect to
mportant clinical and angiographic features. Interlabora-
ory variability in the determination of serum CK concen-
ration must be recognized (31), and the findings of this
tudy should not be misconstrued to suggest that a specific
K level, or cutoff, can be used for the purposes of
rognostication or selection of treatment strategies. It is also
orth noting that patients with some conditions that
nfluence CK levels were either excluded or underrepre-
ented in the CADILLAC trial (e.g., severe renal failure,
habdomyolysis), and that the use of more specific biomar-
y CKpeak
tile 2
eak < 1,458
Quartile 3
1,458 < CKpeak < 2,667
Quartile 4
CKpeak > 2,667 p Trend
.5 1.3 4.7† 0.0001
.6 0.8 0.5 0.37
.3 0.3 0.3 0.80
.2 3.7 1.9 0.31
.0 5.8 6.5 0.52
10.4 57.8  11.8 52.2  11.2† 0.0001
11.6 2.4  11.1 0.65  12.1‡ 0.006
0.69 1.79  0.75 1.73  0.75 0.95
20.7 38.0  23.7 41.3  26.2 0.46
.4 29.6 30.1 0.81
.1 8.8 10.3 0.28
.6 4.0 7.1† 0.0002
.1 1.3 3.3 0.36
.3 0.8 0.6 0.65
.7 12.7 10.9 0.19
.2 16.7 18.5 0.63
lograms at baseline and at follow-up were available for 714, 421, and 359 patients,
p  0.02 for quartile 4 compared with quartiles 1 through 3 combined.ed b
Quar
CKp
0
1
0
4
5
2.3 
4.5 
.77 
9.2 
32
7
1
2
0
13
15
ntricu
ned. ‡ified by peak creatine kinase (CKpeak) levels.
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roponins) rather than total CK may add further prognostic
ccuracy. Also, it is possible that a marker detectable sooner
fter AMI onset than CK (e.g., myoglobin) might provide
ncremental prognostic information (2). These limitations
o not detract from the powerful clinical utility of post-PCI
K evaluation, an inexpensive test that is more readily
vailable in certain health care systems than assays for
lternative cardiac biomarkers (32). The implications of CK
ncrease in terms of left ventricular functional recovery
hould be considered within the context of the timing of
rotocol-defined determination of convalescent LVEF at
igure 5. Correlation between peak creatine kinase (CKpeak) and absolu
mprovement in left ventricular ejection fraction from baseline to seven meven-month follow-up and attrition of the study popula- dion, which itself was impacted by CKpeak. Protocol-
pecified blood sampling every eight hours in the present
tudy did not permit accurate calculations of the area under
he CK time-activity curve (33), a potentially more accurate
easure of infarct size determination and prognosis. How-
ver, CK sampling as performed in this study closely reflects
outine clinical practice, and CKpeak is a simpler clinical
easure than time-activity curves. The absolute CKpeak and
ime to CKpeak may have been underestimated in the 6.5%
f patients in whom CKpeak occurred at 24 h, the late peak
ossibly reflecting unsuccessful myocardial reperfusion. Fi-
ally, the applicability of our findings to patient populations
t ventricular ejection fraction measured at seven months (top) and the
(bottom).te lefissimilar to that studied in the CADILLAC trial or in
Table 4. Baseline Features and Outcomes of Patients Stratified by Timing of CKpeak
CKpeak Occurring After PCI
p
Three-Way
Trend
CKpeak Occurring
Before PCI
p
1  2  3 vs. 4
Group 1
Peak at 8 h
(n  1,064)
Group 2
Peak at 16 h
(n  306)
Group 3
Peak at 24 h
(n  99)
Group 4
Peak at Baseline
(n  60)
Baseline features
Age, yrs 59.3  12.1 59.5  12.2 62.1  11.9 0.10 59.2  13.1 0.84
Male gender, % 75.0 69.6 59.6 0.001 76.7 0.56
Diabetes mellitus, % 16.7 15.0 24.2 0.10 20.0 0.49
Symptom onset to angioplasty, h 5.0  3.4 4.9  3.1 5.7  3.5 0.14 7.0  4.2 0.0009
Three-vessel disease, % 16.3 15.0 17.2 0.82 18.3 0.59
Infarct vessel  left anterior descending, % 39.2 29.4 34.3 0.006 40.0 0.68
Reference vessel diameter, mm 2.99  0.55 2.99  0.55 2.97  0.53 0.92 2.85  0.48 0.05
TIMI flow grade 3, % 23.9 28.6 47.4* 0.0001 45.0* 0.0001
LVEF, % 54.0  11.8 58.0  11.6 58.2  13.0 0.0001 55.9  13.0 0.66
Procedural results
Stent implanted, % 57.0 58.5 55.6 0.73 38.3 0.005
Abciximab administered, % 54.4 53.3 40.4 0.04 43.3 0.15
TIMI flow grade 3, % 95.6 97.0 97.9 0.28 93.3 0.30
Myocardial blush grade 3, % 15.4 21.6 19.0 0.12 19.0 0.68
Complete ST-segment elevation resolution, % 62.3 67.4 50.0 0.76 57.1 0.99
CKpeak, U/l 2,201  1,762* 1,389  1,403 1,237  1,701 0.0001 806  1,012 0.0001
Outcomes
30-day clinical follow-up
Death, % 1.2 2.6 3.0 0.23 5.0† 0.052
Reinfarction, % 0.7 0.7 3.1 0.05 1.8 0.47
Disabling stroke, % 0.2 0.3 0.0 0.78 0.0 0.73
Ischemic target vessel revascularization, % 2.5 4.0 8.1 0.009 6.8 0.13
Composite major adverse cardiac events, % 3.9 7.2 12.1 0.0008 11.1 0.03
7-month angiographic follow-up
LVEF, % 58.1  12.6 63.0  11.1 62.3  11.1 0.004 60.9  7.3 0.43
Change in LVEF baseline to follow-up, % 3.0  11.7 3.3  11.6 1.79  12.6 0.89 4.8  13.8 0.39
Binary restenosis, % 32.0 22.3 30.8 0.20 26.3 0.80
Reocclusion of infarct artery, % 9.4 4.2 15.4 0.14 0.0 0.39
1-yr clinical follow-up
Death, % 3.1 4.3 7.2‡ 0.14 6.7§ 0.22
Reinfarction, % 2.2 1.4 5.2 0.10 3.5 0.54
Disabling stroke, % 0.5 0.3 1.1 0.68 0.0 0.59
Ischemic target vessel revascularization, % 12.5 13.3 19.8 0.11 19.2 0.18
Composite major adverse cardiac events, % 15.8 17.2 25.4 0.04 23.3 0.16
*p  0.0001 for comparison with groups 1  2. †p  0.04 for comparison with groups 1  2. ‡p  0.06 for comparison with groups 1  2. §p  0.07 for comparison with groups 1  2.
Abbreviations as in Table 1.
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ONCLUSIONS AND CLINICAL IMPLICATIONS
ndependent of other clinical and angiographic measures,
Kpeak directly correlates with infarct size and long-term
ortality in patients with AMI treated with primary PCI,
nd as such, the assessment of serial CK levels in the first
4 h after admission continues to be of prognostic utility in
he contemporary reperfusion era. Using CKpeak, 25% of
atients will be identified within 24 h of hospital admission
n whom the hazard for one-year mortality is approximately
ve- to six-fold increased, signifying a patient cohort in
hom intensive monitoring and secondary preventative
easures are warranted. Despite successful primary PCI,
ovel strategies must also be identified to further enhance
yocardial salvage and prolong survival in this high-risk
roup.
eprint requests and correspondence: Dr. Gregg W. Stone, The
ardiovascular Research Foundation, 55 East 59th Street, 6th
loor, New York, New York 10022. E-mail: gstone@crf.org.
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